ClinicalTrials.gg
Not yet recruitingNCT06774703Updated Jan 14, 2025

Nemaline Myopathy Clinical Research Network (NM-CTRN)

An observational study in Nemaline Myopathy, sponsored by Stanford University. Not yet recruiting at 6 sites in 2 countries. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by Stanford University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Neuromuscular Diseases with a site in United States — 29 open to participants now, 39 under way, 4 of them phase 3. Neuromuscular Diseases · United States.

Planned enrollment
27th of 46
50 · median 82
Started
2025
with 9 others
Observational
46 of 120
17 open now
Primary completion
2029-12
later than 28 of 38 live
Registered
95th of 120
by date

Among the 120 studies in Neuromuscular Diseases with a site in United States, this one is the 27th largest by planned enrollment of the 46 observational ones that give a count, is one of 10 that started in 2025, is one of 46 observational ones, reaches primary completion later than 28 of the 38 other live ones, and was the 95th registered.

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.

Browse Neuromuscular Diseases studies →

Open to participants now

29 of the 120 studies in Neuromuscular Diseases with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.

This study: 0 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Neuromuscular Diseases with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to establish a research network to help define the natural disease history and clinical outcome measures for Nemaline Myopathy (NM).

Read the detailed description

The long-term aim of this study is to incorporate these outcome measures into clinical trials for NM therapies. Outcome measures to be assessed will be dependent on the participant's age and functional status. Follow-up visits will be conducted either every 3 or 6 months, dependent on age, for a total of 3 years.

03

Conditions studied

  • Nemaline Myopathy

Keywords

  • Neuromuscular disease
  • Observational study
  • Congenital myopathy
  • Nemaline rod
04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be identified through several sources. The primary source will be through our NM-CRN MDA care center network. Participants will also be recruited through the CMDIR and the Beggs Laboratory. Information regarding the study will be disseminated to all MDA clinics through the MDA website and via email to clinic directors. In addition, the study will advertised to families through A Foundation Building Strength, which maintains a patient information website and newsletter.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 0-18 years of age at recruitment
  • Confirmation of Nemaline Myopathy (pathogenic or likely pathogenic mutations in ACTA1 (AD) or NEB (AR)
  • Patient and/or parent or legal guardian must be willing and able to provide

Exclusion criteria

Exclusion Criteria:

  • medical finding on the physical examination, other than NM, that the Investigator deems unsuitable for participation in and/or completion of the study procedures
  • Any confirmed chronic or acute condition or disease affecting any system(s), which could interfere with the results of the study and/or the compliance with the study procedures. This will be subject to the clinical judgement of the Principal Investigator (PI)
  • Participants of ongoing (interventional) clinical trials that assess the efficacy of potential treatments will be excluded
  • Safety concerns
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Individuals with Nemaline Myopathy

    All participants in the study will have a diagnosis of Nemaline Myopathy, with either a pathogenic or likely pathogenic mutation in ACTA1 (AD) or NEB (AR). Participants can be either ambulatory or non-ambulatory and must be between the ages of 0-18.

06

What researchers measure

Primary outcomes

  1. Validate the change over 36 months using the Alberta Infant Motor Scale (AIMS) Score

    The AIMS is a standardized tool used to assess a child's gross motor development in four positions: prone, supine, sitting, and standing. Percentile scores are given from 0-100, with higher percentiles representing higher motor function.

    Time frame: 36 months

  2. Validate the change over 36 months using the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)

    The CHOP-INTEND assesses a child's ability to move their body in a lying down position, supported sitting, and assisted rolling through 16 items.

    Time frame: 36 months

  3. Validate the change over 36 months using the Hammersmith Infant Neurological Examination Section 2 (HINE-2)

    This is a 37-item measure of infant developmental motor milestones divided into the following categories: neurological examination, developmental milestones and behavioral scale, and state of consciousness. Scores for individual categories will be combined into a composite score.This will be performed in participants aged 0-24months. Scores are interpreted in relation to optimality scores and cut-off scores for the participant's age. Higher scores represented higher function.

    Time frame: 36 months

  4. Validate the change in 32-item Motor Function Measure (MFM32) Scale Score

    This motor function assessment consists of 32 items organized in three dimensions: standing position and transfers, axial and limb proximal motor function, and limb distal motor function. Total scores are given between 0-100, with 0 indicating severe functional impairment and 100 indicating no functional impairment.

    Time frame: 36 months

  5. Change in Peabody Developmental Motor Scales (PDMS-3) Scale Score

    This is used to measure various motor abilities in young children. Four types of normative scores are yielded: age equivalents, percentile ranks, subtest scaled scores, and composite index scores. Age equivalents are indexes of relative standing that translate subtest raw scores into motor ages. Percentiles provide the examiner with an index that is easily understood. Subtest scaled scores are based on a distribution having a mean of 10 and a standard deviation of 3. Composite indexes are based on a distribution with a mean of 100 and a standard deviation of 15. Higher scores indicate higher level of function.

    Time frame: 36 months

  6. Change in ambulation over 36 months as measured by the 10 meter walk (m/s).

    This test measures the time taken for a participant to walk 10 metres as quickly and safely as possible. This will be performed in ambulatory participants aged 2 years and older.

    Time frame: 36 months

  7. Change in ambulation over 36 months as measured by the 6 Minute Walk Test

    This is a measure of how far a participant can walk along a track in 6 minutes. This will be performed in ambulatory participants aged 5 years and older.

    Time frame: 36 months

  8. Change in respiratory function over 36 months as measured by spirometry, specifically the supine forced vital capacity (FVC).

    This is a measure (% predicted) of the maximum amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible. This will be performed in participants aged 5 years and older.

    Time frame: 36 months

Secondary outcomes

  1. Change in muscle thickness of lower extremity muscles over 36 months as measured by muscle ultrasound.

    This will be conducted in a subset of participants aged \>5 years.

    Time frame: Baseline through month 36

  2. Skin Biopsy (optional)

    This optional outcome measure involves a one-time removal of three to four 2mm pieces of skin from one body site.

    Time frame: Baseline through month 36

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Dec 2029, 59 months later.

Of 64 non-industry observational studies under Neuromuscular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 114. This study's planned 59 months is above that.

Counting every sponsor, half of 70 studies reached it within 37 months; a quarter within 12 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Jan 14, 2025
StartEst.
Jan 2025
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06774703
Collaborators
A Foundation Building Strength
Responsible party
Carolina Tesi-Rocha (Clinical Professor, Stanford University) — Principal investigator
First posted
Jan 14, 2025
Start date
Jan 2025 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jan 14, 2025

Study contacts

Carolina Tesi-Rocha, MD
Contact
ctesiroc@stanford.edu
650-723-0993
Sarah Ismail, BSc
Contact
sismail@stanford.edu
650-460-4596
Carolina Tesi-Rocha, MD
principal investigator · Stanford University
Tina Duong, PT, PhD
principal investigator · Stanford University
John W Day, MD, PhD
principal investigator · Stanford University
Leslie Hayes, MD
principal investigator · Boston Children's Hospital
Alan Beggs, PhD
principal investigator · Boston Children's Hospital
Jim Dowling, MD, PhD
principal investigator · The Hospital for Sick Children
Richard Finkel, MD
principal investigator · St Jude Children's Hospital
Carsten Bonnemann, MD, PhD
principal investigator · National Institutes of Health (NIH)
Kaitlin Batley, MD
principal investigator · UT Southwestern Medical Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion